A
Atriva Therapeutics
First-in-class inhibitors against seasonal and pandemic influenza
About Atriva Therapeutics
Atriva Therapeutics GmbH is a biopharmaceutical company specializing in the development of antiviral therapies aimed at severe respiratory viral infections, including COVID-19 and influenza. The company operates in the healthcare and pharmaceutical market, focusing on a novel host-targeting approach to prevent viral replication. Atriva's lead product, ATR-002, has shown significant potential due to its antiviral and immunomodulating activity, successfully completing Phase I clinical trials and moving into Phase II for COVID-19 and influenza. The business model revolves around extensive research and development, clinical trials, and eventual commercialization of their antiviral therapies. Revenue is generated through partnerships, licensing agreements, and sales of their proprietary treatments. Atriva's clients primarily include healthcare providers, hospitals, and pharmaceutical companies looking for innovative solutions to combat viral infections.
Source: Dealroom company dataAt a glance
- Founded
- 2015
- Headquarters
- Tübingen, Germany
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A1 investor entered at this stage
Meneldor
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Atriva Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Atriva Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.